Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015)



Despierre, Evelyn, Vergote, Ignace, Anderson, Ryan, Coens, Corneel, Katsaros, Dionyssios, Hirsch, Fred R, Boeckx, Bram, Varella-Garcia, Marileila, Ferrero, Annamaria, Ray-Coquard, Isabelle
et al (show 6 more authors) (2016) Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015). TARGETED ONCOLOGY, 11 (3). 429 - 429.

[img] Text
erratum Despierre.pdf - Unspecified

Download (210kB)
[img] Text
Despierre 2015.pdf - Accepted Version

Download (1MB)
Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 18 Jul 2016 15:41
Last Modified: 02 Oct 2021 07:30
DOI: 10.1007/s11523-016-0433-x
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3001176